Multiple sclerosis (MS) drug, Zinbryta, receives FDA approval

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly. "Zinbryta provides an additional choice to patients who may require a new option for treatment," said Billy Dunn, M.D., director ["]